[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100495907":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":41,"responsibleParty":155,"collaborators":157,"id":177,"slug":36,"hasResults":178,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":36,"eligibilityCriteria":182,"healthyVolunteers":178,"sex":183,"minAge":184,"maxAge":185,"enrollmentInfo":186,"targetDuration":36,"studyType":189,"phases":190,"briefSummary":192,"conditions":193,"keywords":36,"overallStatus":72,"whyStopped":36,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":209},{"fullName":5,"class":6},"Women's Hospital School Of Medicine Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Nab-Paclitaxel\u002Fcarboplatin for systemic therapy after surgery","EXPERIMENTAL","Nab-Paclitaxel\u002Fcarboplatin q3 weeks Nab-Paclitaxel 260 mg\u002Fm² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel\u002Fcarboplatin weekly Dose-dense Nab-Paclitaxel 100 mg\u002Fm2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles",[13],"Drug: nab-paclitaxel combined with carboplatin",{"label":15,"type":16,"description":17,"interventionNames":18},"Paclitaxel\u002Fcarboplatin for systemic therapy","ACTIVE_COMPARATOR","Paclitaxel 175 mg\u002Fm² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles\n\nPaclitaxel weekly\u002Fcarboplatin weekly Paclitaxel 60 mg\u002Fm2 followed by carboplatin AUC（area under the curve） 2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","nab-paclitaxel combined with carboplatin","Nab-Paclitaxel\u002Fcarboplatin q3weeks Nab-Paclitaxel 260 mg\u002Fm² IV followed by carboplatin AUC（area under the curve） 5 IV Day1 Repeat every 21 days x 6 cycles Nab-Paclitaxel\u002Fcarboplatin weekly Dose-dense Nab-Paclitaxel 100 mg\u002Fm2 IV followed by carboplatin AUC（area under the curve）2 IV Davs 1. 8, and 15 ·Repeat every 21 days x 6 cycles Paclitaxel 175 mg\u002Fm² IV followed by carboplatin AUC（area under the curve）5 IV Day·1Repeat every 21 days x 6 cycles\n\nPaclitaxel weekly\u002Fcarboplatin weekly Paclitaxel 60 mg\u002Fm2 followed by carboplatin AUC（area under the curve）2 IV Days 1.8. and 15: repeat every 21 days 6 cycles (18 weeks)",[9,15],[26],"paclitaxel combined with carboplatin",[28],{"name":29,"affiliation":30,"role":31},"Yaxia Chen, MD","Study Principal Investigator","PRINCIPAL_INVESTIGATOR",[33,38],{"name":29,"role":34,"phone":35,"phoneExt":36,"email":37},"CONTACT","+86-571-87061501",null,"chenyax@zju.edu.cn",{"name":39,"role":34,"phone":35,"phoneExt":36,"email":40},"Yang Li, MD","li_yang@zju.edu.cn",[42,59,70,85,93,101,109,117,128,136,147],{"facility":43,"status":44,"city":45,"state":46,"zip":36,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Sun Yat-Sen University Cancer Hospital","NOT_YET_RECRUITING","Guangzhou","Guangdong","China",{"type":49,"coordinates":50},"Point",[51,52],113.25,23.11667,{"lat":52,"lon":51},[55,57],{"name":56,"role":34,"phone":36,"phoneExt":36,"email":36},"Yanling Feng",{"name":58,"role":31,"phone":36,"phoneExt":36,"email":36},"Jihong Liu",{"facility":60,"status":44,"city":61,"state":62,"zip":63,"country":47,"cosmosGeoPoint":36,"geoPoint":36,"contacts":64},"Qilu Hospital of Shandong University","Ji'nan","Shandong","250012",[65,68],{"name":66,"role":34,"phone":36,"phoneExt":36,"email":67},"Jie Jiang","qljiangjie@aliyun.com",{"name":69,"role":31,"phone":36,"phoneExt":36,"email":36},"Beihua Kong",{"facility":71,"status":72,"city":73,"state":74,"zip":75,"country":47,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Yaxia Chen","RECRUITING","Hangzhou","Zhejiang","310006",{"type":49,"coordinates":77},[78,79],120.16142,30.29365,{"lat":79,"lon":78},[82,84],{"name":83,"role":34,"phone":35,"phoneExt":36,"email":40},"Yang Li, Doctor",{"name":71,"role":31,"phone":36,"phoneExt":36,"email":36},{"facility":86,"status":44,"city":73,"state":74,"zip":36,"country":47,"cosmosGeoPoint":87,"geoPoint":89,"contacts":90},"Sir Run Run Hospital",{"type":49,"coordinates":88},[78,79],{"lat":79,"lon":78},[91],{"name":92,"role":34,"phone":36,"phoneExt":36,"email":36},"Jianhua Yang",{"facility":94,"status":44,"city":73,"state":74,"zip":36,"country":47,"cosmosGeoPoint":95,"geoPoint":97,"contacts":98},"The First Affiliated Hospital of Medical College of Zhejiang University",{"type":49,"coordinates":96},[78,79],{"lat":79,"lon":78},[99],{"name":100,"role":34,"phone":36,"phoneExt":36,"email":36},"Jianhua Qian",{"facility":102,"status":44,"city":73,"state":74,"zip":36,"country":47,"cosmosGeoPoint":103,"geoPoint":105,"contacts":106},"The Second Affiliated Hospital of Medical College of Zhejiang University",{"type":49,"coordinates":104},[78,79],{"lat":79,"lon":78},[107],{"name":108,"role":34,"phone":36,"phoneExt":36,"email":36},"Jianwei Zhou",{"facility":110,"status":44,"city":73,"state":74,"zip":36,"country":47,"cosmosGeoPoint":111,"geoPoint":113,"contacts":114},"Zhejiang Cancer Hospital",{"type":49,"coordinates":112},[78,79],{"lat":79,"lon":78},[115],{"name":116,"role":34,"phone":36,"phoneExt":36,"email":36},"Yaqing Chen",{"facility":118,"status":44,"city":119,"state":74,"zip":36,"country":47,"cosmosGeoPoint":120,"geoPoint":124,"contacts":125},"Ningbo women's and children's Hospital","Ningbo",{"type":49,"coordinates":121},[122,123],121.54945,29.87819,{"lat":123,"lon":122},[126],{"name":127,"role":34,"phone":36,"phoneExt":36,"email":36},"Lingjun Zhao",{"facility":129,"status":44,"city":119,"state":74,"zip":36,"country":47,"cosmosGeoPoint":130,"geoPoint":132,"contacts":133},"The No, 1 People's Hospital of Ningbo",{"type":49,"coordinates":131},[122,123],{"lat":123,"lon":122},[134],{"name":135,"role":34,"phone":36,"phoneExt":36,"email":36},"Yutao Guan",{"facility":137,"status":44,"city":138,"state":74,"zip":36,"country":47,"cosmosGeoPoint":139,"geoPoint":143,"contacts":144},"The Second Affiliated Hospital of Wenzhou Medical University","Wenzhou",{"type":49,"coordinates":140},[141,142],120.66682,27.99942,{"lat":142,"lon":141},[145],{"name":146,"role":34,"phone":36,"phoneExt":36,"email":36},"Yan Hu",{"facility":148,"status":44,"city":138,"state":36,"zip":36,"country":47,"cosmosGeoPoint":149,"geoPoint":151,"contacts":152},"The First Affiliated Hospital of Wenzhou Medical University",{"type":49,"coordinates":150},[141,142],{"lat":142,"lon":141},[153],{"name":154,"role":34,"phone":36,"phoneExt":36,"email":36},"Xiaojian Yan",{"type":156,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR",[158,160,162,164,166,168,170,171,173,175],{"name":159,"class":6},"Jiaxing Maternity and Child Health Care Hospital",{"name":161,"class":6},"Zhejiang University",{"name":163,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"name":165,"class":6},"First Affiliated Hospital of Wenzhou Medical University",{"name":167,"class":6},"Second Affiliated Hospital of Wenzhou Medical University",{"name":169,"class":6},"Sun Yat-Sen University Cancer Center",{"name":60,"class":6},{"name":172,"class":6},"Ningbo No. 1 Hospital",{"name":174,"class":6},"Ningbo Women & Children's Hospital",{"name":176,"class":6},"Sir Run Run Shaw Hospital","100495907",false,"NCT05737303","Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer","Nab-paclitaxel Versus Solvent-based Taxanes As First-Line Treatment for Patients With Advanced Ovarian Cancer","Inclusion Criteria:\n\n1. Epithelial ovarian cancer\u002Ftubal cancer\u002Fperitoneal cancer was diagnosed by histopathology or hydroexfoliation cytopathology of the chest and abdomen, and was classified as stage III-IV according to FIGO（International Federation of Gynecology and Obstetrics）stage\n2. Physical condition Eastern Cooperative Oncology Group PS score: 0-2 points\n3. Participants who had not participated in other drug clinical trials within 4 weeks prior to enrollment\n4. Written informed consent\n5. Expected survival ≥6 months\n6. The disease met the criteria for Efficacy Evaluation of solid tumors (RECIST 1.1)\n7. Be able to comply with outpatient treatment, laboratory monitoring, and necessary clinical visits during study participation.\n\nExclusion Criteria:\n\n1. Patients with low malignant potential ovarian tumors;\n2. Other malignant tumors within the previous 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer;\n3. Patients who have previously received chemotherapy or radiotherapy for pelvic cavity;\n4. Patients with central nervous system metastasis or peripheral neuropathy \\> grade 1;\n5. Patients with severe myelosuppression, severe liver dysfunction (Child's Class III), or renal dysfunction at the time of screening;\n6. Severe cardiovascular disease: Grade Ⅱ or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥470 ms); According to NYHA（New York Heart Association） criteria, patients with grade Ⅲ to Ⅳ cardiac insufficiency or left ventricular ejection fraction (LVEF) \\\u003C 55% indicated by color Doppler ultrasonography;\n7. Uncontrolled systemic infection requiring anti-infective treatment;\n8. Arteriovenous thrombosis events occurring within 6 months before randomization, such as cardiovascular and cerebrovascular accidents (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction, myocardial infarction), deep vein thrombosis and pulmonary embolism;\n9. Patients who are allergic to the active ingredients or excipients of albumin paclitaxel and carboplatin for injection;\n10. Pregnant or lactating women;\n11. Those who were considered unsuitable for inclusion by the researchers.","FEMALE","18 Years","75 Years",{"count":187,"type":188},538,"ESTIMATED","INTERVENTIONAL",[191],"PHASE3","The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with solvent-based taxanes as first-line treatment for patients with advanced primary epithelial ovarian cancer (EOC), primary peritoneal carcinoma or fallopian tube carcinoma.",[194,195,196,197,198,199],"Epithelial Ovarian Carcinoma Stage III","Epithelial Ovarian Carcinoma Stage IV","Fallopian Tube Carcinoma Stage III","Fallopian Tube Carcinoma Stage IV","Primary Peritoneal Carcinoma Stage III","Primary Peritoneal Carcinoma Stage IV","2025-02-09",{"date":202,"type":203},"2025-02-11","ACTUAL",{"date":205,"type":203},"2023-11-27",{"date":207,"type":188},"2027-12-31",{"name":5,"class":6},11]